107 related articles for article (PubMed ID: 31756089)
1. A Comparative Study on Albumin-Binding Molecules for Targeted Tumor Delivery through Covalent and Noncovalent Approach.
Um W; Park J; Youn A; Cho H; Lim S; Lee JW; Yoon HY; Lim DK; Park JH; Kim K
Bioconjug Chem; 2019 Dec; 30(12):3107-3118. PubMed ID: 31756089
[TBL] [Abstract][Full Text] [Related]
2. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
[TBL] [Abstract][Full Text] [Related]
3. 2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
Akinboye ES; Rogers OC; Isaacs JT
Prostate; 2018 Jun; 78(9):655-663. PubMed ID: 29572902
[TBL] [Abstract][Full Text] [Related]
4. Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery.
Wei W; He Z; Yang J; Sun M; Sun J
Drug Deliv Transl Res; 2018 Oct; 8(5):1162-1170. PubMed ID: 29748833
[TBL] [Abstract][Full Text] [Related]
5. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.
Warnecke A; Kratz F
Bioconjug Chem; 2003; 14(2):377-87. PubMed ID: 12643748
[TBL] [Abstract][Full Text] [Related]
6. A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity.
Zhao D; Zhang H; Tao W; Wei W; Sun J; He Z
Biomater Sci; 2017 Feb; 5(3):502-510. PubMed ID: 28116362
[TBL] [Abstract][Full Text] [Related]
7. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
[TBL] [Abstract][Full Text] [Related]
8. Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin.
Wang J; Gou Y; Zhang Z; Yu P; Qi J; Qin Q; Sun H; Wu X; Liang H; Yang F
Mol Pharm; 2018 Jun; 15(6):2180-2193. PubMed ID: 29722993
[TBL] [Abstract][Full Text] [Related]
9. A Versatile Platform to Generate Prodrugs with Rapid and Precise Albumin Hitchhiking and High Cargo Loading for Tumor-Targeted Chemotherapy.
Li J; Xing H; Chen J; Lu H; Tao Z; Tao Y; Sun Y; Su T; Li X; Chang H; Chen S; Chen Z; Yang H; Cheng J; Zhu H; Lu X
Small; 2024 Mar; 20(13):e2304253. PubMed ID: 37963821
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
11. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma.
Li H; Wang P; Deng Y; Zeng M; Tang Y; Zhu WH; Cheng Y
Biomaterials; 2017 Sep; 139():30-38. PubMed ID: 28582716
[TBL] [Abstract][Full Text] [Related]
12. Impact of albumin on drug delivery--new applications on the horizon.
Elsadek B; Kratz F
J Control Release; 2012 Jan; 157(1):4-28. PubMed ID: 21959118
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of mesenchymal-epithelial transition factor (c-Met) expression using an optical imaging system.
Kim EM; Park EH; Cheong SJ; Lee CM; Jeong HJ; Kim DW; Lim ST; Sohn MH
Bioconjug Chem; 2009 Jul; 20(7):1299-306. PubMed ID: 19534520
[TBL] [Abstract][Full Text] [Related]
14. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.
Abu Ajaj K; Biniossek ML; Kratz F
Bioconjug Chem; 2009 Feb; 20(2):390-6. PubMed ID: 19199576
[TBL] [Abstract][Full Text] [Related]
15. Albumin-binding prodrugs via reversible iminoboronate forming nanoparticles for cancer drug delivery.
Hao L; Zhou Q; Piao Y; Zhou Z; Tang J; Shen Y
J Control Release; 2021 Feb; 330():362-371. PubMed ID: 33359484
[TBL] [Abstract][Full Text] [Related]
16. Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy.
Chang Y; Yao S; Chen Y; Huang J; Wu A; Zhang M; Xu F; Li F; Huang Y
Nanoscale; 2019 Jan; 11(2):611-621. PubMed ID: 30556550
[TBL] [Abstract][Full Text] [Related]
17. Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.
Wei W; Luo C; Yang J; Sun B; Zhao D; Liu Y; Wang Y; Yang W; Kan Q; Sun J; He Z
J Control Release; 2018 Sep; 285():187-199. PubMed ID: 30017721
[TBL] [Abstract][Full Text] [Related]
18. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery.
Du C; Deng D; Shan L; Wan S; Cao J; Tian J; Achilefu S; Gu Y
Biomaterials; 2013 Apr; 34(12):3087-97. PubMed ID: 23374705
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles: Preparation, characterization, and targeting effect on liver tumors.
Wu M; Lian B; Deng Y; Feng Z; Zhong C; Wu W; Huang Y; Wang L; Zu C; Zhao X
J Biomater Appl; 2017 Aug; 32(2):191-205. PubMed ID: 28610486
[TBL] [Abstract][Full Text] [Related]
20. HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach.
Yang F; Liang H
Future Med Chem; 2016; 8(2):89-91. PubMed ID: 26824398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
